Heart valve replacement co takes in $3.5m
This article was originally published in Clinica
Swiss start-up Symetis has raised SwFr4m ($3.5m) to fund the first-in-man (FIM) trial of its StentValve percutaneous valve replacement system. The financing was provided by Wellington Partners and existing investors Truffle Capital, Novartis Venture Fund and Aravis Venture. According to Lausanne-based Symetis, the StentValve has a distinctive self-positioning design, that allows the replacement valve to be delivered via the transapical or transfemoral route. The company, headed by Dr Jacques Essinger, of Aravis Venture, is currently carrying out preclinical testing and expects to initiate FIM trial by mid-2009.